Navigation Links
Chimerix Completes $45 Million Financing to Fund Further Development of Novel Antiviral Therapeutics CMX001 and CMX157
Date:2/14/2011

DURHAM, N.C., Feb. 14, 2011 /PRNewswire/ -- Chimerix, Inc., a pharmaceutical company developing orally-available broad spectrum antiviral therapeutics, today announced the completion of a $45 million Series F financing. New Leaf Venture Partners led the round, with participation by new investors Pappas Ventures and Morningside Group, as well as existing investors Canaan Partners, Sanderling Ventures, Alta Partners, Asset Management Company and Frazier Healthcare Ventures.

Proceeds from this financing will be used to support the development of Chimerix's two clinical-stage candidates, CMX001 and CMX157.  CMX001 is in clinical development as a broad spectrum antiviral for the treatment of life-threatening viral infections in immunocompromised patients, and has a potential dual use as a medical countermeasure in the event of a smallpox release.  Chimerix is evaluating CMX001 in an ongoing Phase 2 clinical study of cytomegalovirus (CMV) in hematopoietic stem cell transplant patients, and in an Open-Label Study under an expanded access protocol for the treatment of critically-ill patients with any of 12 different double-stranded DNA viral infections.  A Phase 2 clinical trial of CMX001 in pediatric and adult hematopoietic stem cell transplant patients with adenovirus related diseases is currently being initiated. Chimerix recently completed a Phase 1 clinical trial of CMX157, a potent nucleoside analogue in development for the treatment of HIV infections, including those caused by multi-drug resistant viruses.

"Development of our two clinical-stage antiviral therapeutics is rapidly accelerating.  We are truly pleased to receive this strong support from leading life science investors for Chimerix's ground-breaking programs," said Kenneth I. Moch, President and CEO of Chimerix. "We are extremely enthusiastic about the very real prospects for Chimerix's drugs to dramatically improve the treatment of deadly viral infections."  

<
'/>"/>
SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Chimerix Presents Update on CMX001 Development to the World Health Organization Advisory Committee on Variola Virus Research
2. Chimerixs PIM Conjugate Technology Reduces Risk of Nephrotoxicity for CMX001 and CMX157
3. Chimerix Appoints Two New Vice Presidents to Clinical Management Team
4. Chimerix to Present at Upcoming Investor Conferences
5. Chimerix Initiates Phase 1 Study of CMX157
6. Chimerix Names George Painter, Ph.D., Chairman of the Board and Chief Scientific Officer; Appoints Kenneth I. Moch President and Chief Executive Officer
7. Chimerix Names Wendy Painter, M.D., M.P.H., as Chief Medical Officer
8. Chimerix, Inc. Appoints Kenneth I. Moch Chief Operating Officer
9. Chimerix Joins International Network of Organizations to Cure Malaria
10. Chimerix Completes Phase I Study and Initiates a Phase II Multi-dose Clinical Trial for CMX001
11. Cognition Therapeutics Completes $2.5M in Series A1 Financing to Advance Alzheimers Disease Drug Treatment Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... The report expects global cell isolation and expansion market ... a carefully analyzed data about the vital drivers, restraints, ... Full Copy of Report @ http://bit.ly/1yUxy0T , ... expansion will keep witnessing growth at an impressive CAGR ... driven by rapid technological advancements, government funding and investments, ...
(Date:12/24/2014)... BEIJING , Dec. 23, 2014 ... or the "Company"), a leading fully integrated plasma-based ... today announced that its majority-owned subsidiary, Shandong Taibang ... Practices ("GMP") certification from the China Food and ... factor production facility. As previously disclosed in the ...
(Date:12/24/2014)... 2014 PharmaBoardroom,s new report, ... and available for free download , digs deep into ... growth in the sector today. One area where ... been in developing a homegrown pharmaceutical manufacturing base, even if ... remains some way off. A cursory comparison with neighboring ...
(Date:12/24/2014)... -- Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI ) ... Application (CTA) with the United Kingdom,s ... approval to initiate clinical trials for the continued development ... on the Company receiving CTA regulatory approval, the Company ... the safety, tolerability and dose escalation of Anatabine Citrate ...
Breaking Biology Technology:The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3
... Romark Laboratories, L.C., a,privately-owned biotechnology company, ... has joined the Company as Vice President ... Keeffe served as Professor of Medicine, Chief ... Program at Stanford,University Medical Center. He is ...
... NATICK, Mass., Jan. 4 Boston Scientific,Corporation ... has completed the sale of,the controlling interests in ... former principals and shareholders of Advanced,Bionics. Boston Scientific ... the closing of the amended merger agreement with ...
... International,Corporation (Nasdaq: PRXL ) will release Second Quarter ... after the close of the,stock market. The announcement will ... on the PR Newswire website at, http://www.prnewswire.com ., ... at 10:00 a.m. ET,on Thursday, January 24, 2008 to ...
Cached Biology Technology:Romark Laboratories Names Emmet B. Keeffe, M.D. Vice President and Chief Medical Officer 2Boston Scientific Completes Sale of Auditory Business and Drug Pump Development Program 2Boston Scientific Completes Sale of Auditory Business and Drug Pump Development Program 3PAREXEL Announces Date of Second Quarter Fiscal Year 2008 Earnings Release and Conference Call 2
(Date:12/5/2014)... 4, 2014  Tute Genomics, a leader in cloud-based ... Series A1 funding led by UK-based Eurovestech. Peak Ventures ... the investment round. "We are at a ... next-generation sequencing and seeks new approaches for the diagnosis, ... , MD MBA, and CEO of Tute Genomics. "One ...
(Date:12/3/2014)... Dec. 2, 2014   Marvin Test Solutions ... test solutions for military, aerospace, and manufacturing organizations, ... its successful TS-900 PXI semiconductor test platform ... of high-end systems to customers at a fraction ... to traditional ATE. "Our semiconductor ...
(Date:11/21/2014)... , November 18, 2014 ... Systems Market by Systems (Video, RFID, Access Control, Intrusion ... Factories, Hotels, Banks, Government), Component Service Geography - Global ... Systems Market is projected to be around $25 Billion ... by 2020, growing at a CAGR of 8.69%. ...
Breaking Biology News(10 mins):Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3
... The phenomenon of light emission by living organisms, bioluminescence, ... known that light is generated by chemical reactions in ... animal world, these chemical reactions take place in special ... light organs, in which the intensity of light is ...
... today (Monday) to advise the country on how it ... The biotechonology experts from the Belfast-based University are ... cost the world economy around $200 billion in lost ... year. A delegation led by Dr Gerry Brennan ...
... Nottingham have devised a method for identifying levels of ... Arsenic occurs naturally in the environment and ... for example through contaminated water, food, dust or soil. ... of the UK where the natural geology and historic ...
Cached Biology News:New light shed on marine luminescence 2Reduction in parasite infections ahead for India 2Arsenic and old toenails 2
(3-[125I]iodotyrosyl26)Galanin, porcine, 370 kBq, 10 uCi. Category: IODINE LIGANDS....
Terrific Broth, 1 kg. Mixture of casein peptone, yeast extract, K2HPO4, and KH2PO4.Used at 47 g/l for E. coli growth with higher cell densities. Category: Nucleotides & Enzymes & Biochemicals, Ultrap...
Homo sapiens postsynaptic protein CRIPT Antigen: Recombinant Protein...
Human VEGF R3/Flt-4 Phycoerythrin MAb (Clone 54733)...
Biology Products: